The influence of obesity on hyperandrogenism and infertility in the female
E. Diamanti-Kandarakis
Endocrine Section of 1st Department of Internal Medicine, Laiko General Hospital, Athens University, Athens, Greece
Search for more papers by this authorA. Bergiele
Endocrine Section of 1st Department of Internal Medicine, Laiko General Hospital, Athens University, Athens, Greece
Search for more papers by this authorE. Diamanti-Kandarakis
Endocrine Section of 1st Department of Internal Medicine, Laiko General Hospital, Athens University, Athens, Greece
Search for more papers by this authorA. Bergiele
Endocrine Section of 1st Department of Internal Medicine, Laiko General Hospital, Athens University, Athens, Greece
Search for more papers by this authorAbstract
Although a critical mass of adipose tissue is essential for the normal development of female reproductive function, obesity has been shown to produce menstrual disturbances and subfertility. The severity of obesity and the distribution of fat tissue are important factors that influence the female reproductive system. The pathogenetic mechanistic links between them aren’t clearly elucidated. Obese women, especially those with upper body obesity, have insulin resistance and hyperinsulinaemia, hyperandrogenaemia, increased peripheral aromatization of androgens to oestrogens, altered gonadotrophin secretion, decreased sex hormone binding globulin, decreased growth hormone (GH) and insulin like growth factor binding proteins (IGFBPs), increased leptin levels and altered neuroregulation of the hypothalamic-pituitary-gonadal axis. These have been considered as some of the links in the sequence of events of the disrupted ovulatory process. The mechanisms of these actions and their influence on female reproductive function are discussed below.
References
- 1 Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960–1990. JAMA 1994; 272: 205–211.
- 2 Manson JE, Willet WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med 1995; 333: 677–685.
- 3 Frisch RE. Body fat, menarche and ovulation. Bailieres Clin Obstet Gynecol 1990; 4: 419–439.
- 4 Grodstein F, Goldman MB, Cramer DW. Body mass and ovulatory inferility. Epidemiology 1994; 5: 247–250.
- 5 Hartz AJ, Barboriak PN, Wong A, Katayama KP, Rimm AA. The association of obesity with infertility and related menstrual abnormalities in women. Int J Obesity 1979; 3: 57–73.
- 6 Harlass FE, Plymate SR, Farris BL, Belts RP. Weight loss is associated with correction of gonadotrophin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984; 42: 649–652.
- 7
Kopelman PG.
Neuroendocrine function in obesity.
Clin Endocrinol
1998; 28: 675–690.
10.1111/j.1365-2265.1988.tb03860.x Google Scholar
- 8 Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499–507.
- 9 Pasquali R, Cassimirri F, Vicenatti V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Repod 1997; 12: 82–87.
- 10 Lefebvre P, Bringer J, Renard E, Boulet F, Clouet S, Jaffiol C. Influences of weight, body fat patterning and nutrition on the management of PCOS. Hum Reprod 1997; 12: 72–81.
- 11 Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoprotein, and cardiovascular disease. Arteriosclerosis 1990; 10: 497–511.
- 12 Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS. Distribution and characterization of insulin and insulin-like growth factor 1 receptors in normal human ovary. J Clin Endocrinol Metab 1985; 61: 728–734.
- 13 Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstendione by isolated theca cells from polycystic ovaries. J Clin Endocrinol Metabol 1994; 79: 1158–1165.
- 14 Watson H, Willis D, Mason H, Franks S. The effects of ovarian steroids, epidermal growth factor, insulin and insulin-like growth factor-1 on ovarian stromal growth. Proceedings of the Endocrine Society, 79th Annual Meeting, June 11–14. Endocrine Society Press: Bethesda, 1997, pp 389.
- 15 Conley A & Bird I. The role of cytochrome P450 17α-hydroxylase and 3β-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the Δ5- and Δ4-pathways of steroidogenesis in mammals. Biol Reprod 1997; 56: 789.
- 16 Dunaif A, Xia J, Book C-B, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801– 810.
- 17 Miller W, Auchus R, Geller D. The regulation of 17,20 lyase activity. Steroids 1997; 62: 133.
- 18 Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocrine Rev 1992; 13: 641–669.
- 19 Rutanen EM, Pekonen F, Makinen T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor 1 to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine resulation of growth factor action. J Clin Endocrinol Metab 1988; 66: 173–180.
- 20 Jalkanen J, Suikkari Am Koistinen R, Butzow R, Ritvos O, Seppala M, Ranta T. Regulation of insulin-like growth fator – binding protein-1 production in human granulosa-luteal cells. J Clin Endocrinol Metab 1989; 69: 1174–1179.
- 21 Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin like growth factor-binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992; 74: 1355–1360.
- 22 Diamanti-Kandarakis E & Dunaif A. New perspectives in polycystic ovary syndrome. Trends Endocrinol Metab 1996; 7: 267–271.DOI: 10.1016/s1043-2760(96)00125-7
- 23 Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M. Insulin infusion amplifies 17-alpha-hydroxy-corticosteroid intermediate response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996; 81: 881–886.
- 24 Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, Polson DW, Reed MJ, Franks S. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990; 32: 213–220.
- 25 Diamanti-Kandarakis E, Couli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. European J Endocrinol 1998; 138: 269–274.
- 26 Willis D, Mason H, Gilling Smith C, Franks S. Modulation by insulin of follicle stimulating hormone and luteinizing hormone action in human granulosa cells from normal and polycystic ovaries. J Clin Endocrinol Metab 1998; 81: 302–309.
- 27 Mason HD, Willis DS, Beard RW, Winston RM, Margara R, Franks S. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and to concentrations of sex steroids in follicular fluid. J Clin Endocrinol Metab 1994; 79: 1355–1360.
- 28 Franks S, Robinson S, Willis D. Nutrition, insulin and polycistic ovary syndrome. Rev Reprod 1996; 1: 47–53.
- 29 Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994; 9: 188–191.
- 30 Wade G & Schneider J. Metabolic fuels and Reproduction in Female Mammals. Neuroscience Behav Reviews 1992; 16: 232–272.
- 31 Kalra PS, Kalra SP, Krulich L, Fawcett CP, McCann SM. Involvement of norepinephrine in transmission of the stimulatory influence of progesterone on gonadotrophin release. Endocrinology 1972; 90: 1168–1176.
- 32 Kalra PS & Kalra SP. Opioid adrenergic steroid connection in regulation of luteinizing hormone secretion in the rat. Neuroendocrinology 1984; 38: 418–426.
- 33 Kalra SP, Clark JT, Sahu A, Hypothalamic NPY. A local circuit in the control of reproduction and behavior. In: Mutt V (ed). Neuropeptide Y. Raven Press: New York, 1989, pp 229–241.
- 34 Pasquali R, Cantobelli S, Casimirri F, Bortoluzzi L, Boschi S, Capelli M, Barbar L. The role of opioid peptides in the development of hyperinsulinemia in obese women with abdominal body fat distribution. Metabolism 1992; 41: 763–767.
- 35 Feldman M, Kiser RS, Unger RH, Li CH. β-endorphin and the endocrine pancreas Studies in healthy and diabetic human being. N Engl J Med 1983; 308: 349–353.
- 36 Mantzoros XS, Dunaif A, Flier JS. Leptin conentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 1687–1691.
- 37 Hileman AM, Pierroz DD, Flier JS. Leptin, Nutrition, and Reproduction: Timing is everything. J Clin Endocrinol Metab 2000; 85: 804–807.
- 38 Barash IA, Cheung CC, Weigle DS, Ren H, Kabigting EB, Kuijper JL, Clifton DK, Steiner RA. Leptin is a metabolic signal to the reproductive system. Endocrinology 1996; 137: 3144– 3147.
- 39 Vincenatti V, Gambineri F, Calzoni F, Cassimirri F, Macor C, Vettor R, Pasquali R. Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 1998; 47: 988–992.
- 40 Schwartz MW, Baskin DY, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte DJr, Woods SC, Seely RJ, Weigle DS. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45: 513–535.
- 41 Branowska B, Waslewska-Dziubinska E, Radzikowska M, Plonowski A, Roguski K. NPY, galanin and leptin release in women with obesity and in women with anorexia nervosa. Meta Clin Exp 1997; 46: 1394–1389.
- 42 Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: apowerful neurochemical inducer of hyperphagia and obesity. Peptides 1986; 7: 1189–1192.
- 43 Bauer-Dantoin AC, McDonald JK, Levine JE. Neuropeptide Y potentiates luteinizing hormone (LH) -releasing hormone induced LH secretion only under conditions leading to preovulatory LH surges. Endocrinology 1992; 31: 2946–2952.
- 44 Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud B. Chronic intracerebroventricular neuropeptide Y administration to normal rats mimcshormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753–1758.
- 45 Rossmanith WG, Marks DL, Clifton DK, Steiner RA. Induction of galanin expression in gonadotrophin releasing hormone neurons with puberty in the rat. Endocrinology 1994; 135: 140– 148.
- 46 Lopez FJ, Meade EHJr, Negro-Vilar A. endogenous galanin modulates the gonadotrophin and prolactin proestrous surges in the rat. Endocrinology 1993; 132: 795–800.
- 47 Peraldi P & Spiegelman B. TNF-a and insulin resistance: summary and future prospects. Mol Cell Biochem 1998; 182: 169–175.DOI: 10.1023/a:1006865715292
- 48 Adashi EY. The potential relevance of cytokines to ovarian physiology: the emerging role of resident ovarian cells of the white blood cell series. Endocr Rev 1990; 11: 454–464.
- 49 Cianci A, Calogero AE, Palumbo MA, Burrello N, Ciotta L, Palumbo G, Bernardini R. Relationship between tumor necrosis factor and sex steroid concentrations in the follicular fluid of women with immunological infertility. Human Reprod 1996; 11: 265–268.
- 50 Hayes FJ, Hall JE, Boepple PA, Crowley WFJr. Differential control of gonadotrophin secretion in the human: endocrine role of inhibin. J Clin Endocrinol Metab 1998; 83: 1835–1841.
- 51 Woodruff TK & Mather JP. Inhibin, activin and the female reproductive axis. Annu Rev Physiol 1995; 57: 219–244.
- 52 Udoff LC & Adashi EY. Intraovarian regulation of ovarian androgen secretion in PCOs. In: Azziz R, Nestler JE, Dewailly D (eds). Androgen Excess Disorders in Women. Lippincott-Raven: Philadelphia, 1997, pp 295–301.
- 53 Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A, Dewailly D. Serum levels of inhibin are differentially altered in patients with polycystic ovary syndrome; effects of being overweight and relevance to hyperandrogenism. Fertil Steril 2000; 73: 972–977.
- 54 Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81: 2854–2864.
- 55 Yen SSC. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980; 12: 177–208.
- 56 Evans DJ, Barth JH, Burke CW. Body fat topography in women with androgen excess. Int J Obes 1988; 12: 157–162.
- 57 Mantzoros CS, Georgiadis EI, Evangelopoulou K, Katsilambros N. Dehydroepiandrosterone sulfate and testosterone are indepedently associated with body fat distribution in premenopausal women. Epidemiology 1996; 7: 513–516.
- 58 Kissebah AH & Peiris AN. Biology of regional fat distribution: relationship to non-insulin dependent diabetes mellitus. Diab Metab Rev 1989; 5: 83–109.
- 59 Bonora E, Micciolo R, Ghiatas AA, Lancaster JL, Alyassin A, Muggeo M, DeFronzo RA. Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal adipose tissue from simple anthropometric measurements? Metabolism 1995; 44: 1617–2625.
- 60 Bringer J, Lefebvre P, Boulet F, Grigorescu F, Renard E, Hedon B, Orsetti A, Jaffiol C. Body fat composition and regional fat distribution in polycystic ovarian syndrome. Ann New York Acad Sci 1993; 687: 115–123.
- 61 Hippocrates. Airs, Waters, Places (an essay on the influence of climate, water supply and situation on health). In: Hippocratic Writings, Translated by J Chadwick and WN Mann. Penguin Classics: London, 1978, pp 164–165.